What question did this study set out to answer?

The study aims to assess the safety, dosimetry, and initial efficacy of 61Cu-PSMA for prostate cancer imaging.

January 22, 2026

Abstract B054: Phase 1 study of 61Cu-NU101 in patients with prostate cancer

Key Points

The study aims to assess the safety, dosimetry, and initial efficacy of 61Cu-PSMA for prostate cancer imaging.
Conducted a phase 1 trial with 8 subjects having PSMA-avid disease.
Administered 4.2-8.6 mCi of 61Cu-PSMA and performed PET/CT imaging at 1, 2, and 4 hours post administration.
Compared the number of malignant lesions and radiotracer uptake between 61Cu-PSMA and 18F-Piflufolastat.
4-hour imaging with 61Cu-PSMA showed the most suspected malignant lesions and highest uptake in those lesions.
In 4 of 8 subjects, 61Cu-PSMA identified more suspected malignant lesions than 18F-Piflufolastat.
No adverse events were reported, indicating safety of the radiotracer.

Abstract

Abstract Background: Prostate Specific Membrane Antigen (PSMA) -targeted Positron Emission Tomography (PET) has revolutionized prostate cancer imaging, but sensitivity at low PSA levels is still problematic, and delivery of these agents is limited due to the short half-life of many PET radioisotopes. 61Cu is a positron emitter with favorable physical characteristics, which allows for delivery of agents over long distances and delayed imaging which may improve sensitivity. This phase 1 trial was designed to evaluate the safety, dosimetry, optimal imaging parameters, and initial efficacy of a 61Cu-labelled PSMA-targeting radiotracer, 61Cu-NODAGA-PSMA I 2026 Jan 20-22; Philadelphia PA. Philadelphia (PA): AACR; Cancer Res 2026;86 (2Suppl): Abstract nr B054.

Ask AI

Helpful

Bookmark